183 related articles for article (PubMed ID: 8656006)
1. Iron overload as a mechanism for the lowered survival in AIDS patients receiving dapsone-iron protoxalate for secondary prophylaxis of Pneumocystis carinii pneumonia.
Weinberg GA
J Infect Dis; 1996 Jul; 174(1):241-2. PubMed ID: 8656006
[No Abstract] [Full Text] [Related]
2. Does dapsone increase mortality when given for prophylaxis of Pneumocystis carinii pneumonia?
Opravil M; Hirschel B; Lüthy R
AIDS; 1996 Aug; 10(9):1045-6. PubMed ID: 8853742
[No Abstract] [Full Text] [Related]
3. Adverse reactions associated with dapsone therapy in HIV-positive patients: a case presentation and review.
Stroup JS; Stephens JR; Reust R; Miller JA
AIDS Read; 2006 Jan; 16(1):47-8, 53-5; discussion 54-5. PubMed ID: 16433472
[TBL] [Abstract][Full Text] [Related]
4. Acute generalised exanthematous pustulosis induced by Pneumocystis jirovecii pneumonia prophylaxis with dapsone.
Vas A; Laws P; Marsland A; McQuillan O
Int J STD AIDS; 2013 Sep; 24(9):745-7. PubMed ID: 24026795
[TBL] [Abstract][Full Text] [Related]
5. Low-dose dapsone, co-trimoxazole, and survival in Pneumocystis carinii primary prophylaxis.
Antinori A; Murri R; Ammassari A
AIDS; 1996 Aug; 10(9):1046-7. PubMed ID: 8853743
[No Abstract] [Full Text] [Related]
6. Alternative dapsone dosage regimen for prophylaxis of Pneumocystis carinii pneumonia.
Gatti G; Fioredda F; Lorusso C; Cruciani M; Bassetti D
Pediatr Infect Dis J; 1996 Feb; 15(2):183-4. PubMed ID: 8822303
[No Abstract] [Full Text] [Related]
7. Lower survival in AIDS patients receiving dapsone compared with aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia. Study Group.
Salmon-Ceron D; Fontbonne A; Saba J; May T; Raffi F; Chidiac C; Patey O; Aboulker JP; Schwartz D; Vildé JL
J Infect Dis; 1995 Sep; 172(3):656-64. PubMed ID: 7658056
[TBL] [Abstract][Full Text] [Related]
8. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group.
El-Sadr WM; Murphy RL; Yurik TM; Luskin-Hawk R; Cheung TW; Balfour HH; Eng R; Hooton TM; Kerkering TM; Schutz M; van der Horst C; Hafner R
N Engl J Med; 1998 Dec; 339(26):1889-95. PubMed ID: 9862944
[TBL] [Abstract][Full Text] [Related]
9. Drug-resistant Pneumocystis carinii.
Meshnick SR
Lancet; 1999 Oct; 354(9187):1318-9. PubMed ID: 10533856
[No Abstract] [Full Text] [Related]
10. The sulfone syndrome in a patient receiving dapsone prophylaxis for Pneumocystis carinii pneumonia.
Mohle-Boetani J; Akula SK; Holodniy M; Katzenstein D; Garcia G
West J Med; 1992 Mar; 156(3):303-6. PubMed ID: 1595261
[No Abstract] [Full Text] [Related]
11. Atovaquone compared with dapsone to prevent Pneumocystis carinii pneumonia.
Horowitz HW; Wormser GP
N Engl J Med; 1999 May; 340(19):1512-3. PubMed ID: 10328722
[No Abstract] [Full Text] [Related]
12. Toxicity and efficacy of daily vs. weekly dapsone for prevention of Pneumocystis carinii pneumonia in children infected with human immunodeficiency virus. ACTG 179 Study Team. AIDS Clinical Trials Group.
McIntosh K; Cooper E; Xu J; Mirochnick M; Lindsey J; Jacobus D; Mofenson L; Yogev R; Spector SA; Sullivan JL; Sacks H; Kovacs A; Nachman S; Sleasman J; Bonagura V; McNamara J
Pediatr Infect Dis J; 1999 May; 18(5):432-9. PubMed ID: 10353516
[TBL] [Abstract][Full Text] [Related]
13. Reasons for failure of prophylaxis for Pneumocystis carinii pneumonia.
Edge MD; Rimland D
AIDS; 1999 May; 13(8):991-2. PubMed ID: 10371182
[No Abstract] [Full Text] [Related]
14. Comparison of trimethoprim-sulfamethoxazole, dapsone, and pentamidine in the prophylaxis of Pneumocystis carinii pneumonia.
Warnock AC; Rimland D
Pharmacotherapy; 1996; 16(6):1030-8. PubMed ID: 8947975
[TBL] [Abstract][Full Text] [Related]
15. Bilateral upper-lobe cavitary Pneumocystis carinii pneumonia in a patient on dapsone prophylaxis.
Jawahar DA; Dama S; Miarrostami R; Sadagdhar H; Anandarao N
Am J Med Sci; 1999 Feb; 317(2):137-9. PubMed ID: 10037118
[TBL] [Abstract][Full Text] [Related]
16. Dilemmas in the prophylaxis of Pneumocystis carinii pneumonia.
Glatt AE
South Med J; 1994 Apr; 87(4):429-30. PubMed ID: 8153765
[TBL] [Abstract][Full Text] [Related]
17. Successful desensitization to dapsone for Pneumocystis carinii prophylaxis in an HIV-positive patient.
Cook DE; Kossey JL
Ann Pharmacother; 1998 Dec; 32(12):1302-5. PubMed ID: 9876811
[TBL] [Abstract][Full Text] [Related]
18. A controlled trial of dapsone versus pyrimethamine-sulfadoxine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmosis in patients with AIDS.
Payen MC; De Wit S; Sommereijns B; Clumeck N
Biomed Pharmacother; 1997; 51(10):439-45. PubMed ID: 9863502
[TBL] [Abstract][Full Text] [Related]
19. Hepatic and pulmonary pneumocystosis during primary prophylaxis for Pneumocystis carinii pneumonia with dapsone/pyrimethamine.
Podzamczer D; Martos A; Ferrer I; Santin M; Gudiol F
Clin Infect Dis; 1993 Jan; 16(1):171. PubMed ID: 8448298
[No Abstract] [Full Text] [Related]
20. Symptomatic hyperbilirubinemia secondary to dapsone-induced hemolysis and atazanavir therapy.
East J; Blanton LS
Antimicrob Agents Chemother; 2012 Feb; 56(2):1081-3. PubMed ID: 22123706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
